|
|
 |
|
 |
Fitzsimons Redevelopment Authority - Aurora, Colorado
Colorado - Bioscience Industry Leadership
Fitzsimons Redevelopment Authority Board of Directors - Bioscience
Industry Leadership (pictured left to right above, bios follow in order below):
Donald M. Elliman, Jr. (representing Children’s Hospital
Colorado on the FRA Board) -- In February of 2011, Mr. Elliman was named Executive Director of the Charles C. Gates Center
for Regenerative Medicine and Stem Cell Biology. From June of 2009 to January of 2011, Don served as Chief Operating Officer
for Colorado. In that position he assisted the Governor in the management of all State agencies. He was also the Chair of
the Colorado Recovery Accountability Board, with responsibilities for oversight of spending in Colorado under the American
Recovery and Reinvestment Act. From 2007 to 2009, he was Director of the Colorado Office of Economic Development and International
Trade, and from 2000 to 2004, he served first as President of Ascent Sports and then as President of Kroenke Sports Enterprises.
He retired from Kroenke as he became Chair of the Children’s Hospital Board and co-chair of the campaign to raise funds
for the new Hospital. Prior to his time at Kroenke, Mr. Elliman worked at Time Warner for thirty-two years, retiring as an
Executive Vice President of Time Inc. He currently serves on the Boards of Children’s Hospital Colorado, Middlebury
College, Colorado State University and The Gates Family Foundation.
William Freytag, PhD -- Dr. Freytag currently serves as a
member of the board of directors for three health care companies: GlobeImmune, BaroFold, and BiOptix Inc. Dr. Freytag was
Chairman and Chief Executive Officer of Aspreva Pharmaceuticals from July 2007 until its merger with Galenica AG in January
2008. Prior to Aspreva, Dr. Freytag was President, Chief Executive Officer and Chairman of the Board of Directors of Myogen,
Inc., a company that started in the bioscience incubator at Fitzsimons, from July 1998 until Myogen was acquired by Gilead
Sciences in November 2006. From October 1994 to May 1998, Dr. Freytag was a Senior Vice President at Somatogen, Inc. Prior
to Somatogen, Dr Freytag was President of Research and Development at Boehringer Mannheim Corporation, an international healthcare
company. He received a B.S. from Purdue University and a Ph.D. in biochemistry from the University of Kansas Medical Center.
James C. T. Linfield -- As Partner-in-Charge of the Colorado
office of Cooley LLP, Mr. Linfield's practice focuses on representation of public and private technology companies and venture
capital funds, with an emphasis on corporate finance, mergers and acquisitions and strategic alliances. He has deep experience
advising start-ups, venture-backed companies, public entities and investors across a wide variety of industries, including
biotechnology and medical devices. Prior to joining Cooley, Mr. Linfield worked in the biotechnology industry for two and
a half years as Chief Financial Officer and General Counsel of Somatogen, Inc., where he helped lead the company to a successful
initial public offering. He received his A.B. magna cum laude from Harvard College and his J.D. magna cum laude from Harvard
Law School. He also serves as Chair of the Governor’s Advisory Committee on Venture Capital Investment, is a member
of the Executive Committee of the Colorado BioScience Association, and is a member of the Technology Transfer Advisory Board
for the University of Colorado.
David Perez -- As President and Chief Executive Officer of
the combined businesses of CaridianBCT and Terumo Transfusion—soon to be Terumo BCT, Mr. Perez also serves as Chairman
of Terumo Corporation’s Blood Management Business board. He is responsible for leading the strategic direction, growth
and execution of this combined global organization with revenues in excess of $830 million. Under his leadership direction,
the companies will integrate and innovate, together, to serve customers and their patients, who are the ultimate beneficiaries
of the lifesaving gift of blood. A dedicated and active industry leader with nearly 30 years of experience within the
medical device and health care industries, Mr. Perez also lends his expertise to numerous boards and councils. He serves the
Advanced Medical Technology Association (AdvaMed) on the board of directors and on the Executive Committee, chairing both
the Technology and Regulatory Affairs Committee and the Blood Products and Technology Sector. Mr. Perez is also chair of the
board of trustees for the National Blood Foundation (NBF); a member of the NBF Council on Research and Development; and a
board member of the Foundation for America's Blood Centers® and the Colorado BioScience Association. Prior to joining
CaridianBCT in 1999, he held leadership positions at UroTherapies Inc., Haemonetics® Corp., Caremark LLC, Coram Healthcare
Corp. and Kendall. Mr. Perez earned his bachelor's degree in political science from Texas Tech University.
Other FRA Board members include: Bruce Benson, President, University of Colorado;
Bruce Schroffel, President, University of Colorado Hospital; John Shaw, Principal, McWhinney; Lilly Marks, Vice President
for Health Affairs and Executive Vice Chancellor of the Anschutz Medical Campus; Dwight Rider, Principal, Fruend Investments;
and Councilwoman Melissa Miller from Aurora who will be joined by two other elected officials to be named by the Aurora City
Council.
E-mail for additional information
News Release Archive:
The Fitzsimons Redevelopment Authority (FRA) is expanding its Bioscience
Park Center (BPC) by roughly 50% with an $8 million, 37,000-square-foot accelerator structure. The new accelerator space will
be leased to existing tenants graduating from the incubator and other companies in the modest growth stage. - December 12,
2011
The Fitzsimons Redevelopment Authority (FRA) is adding four of the area's most
well-known and successful leaders in the Bioscience Industry to its Board of Directors. Change in board composition is the
result of a strategic refocus for the FRA, and those recently appointed to the board include: Donald M. Elliman, Jr.; William
Freytag, PhD; James C. T. Linfield; and David Perez. - November 15, 2011
|
|
 |